Telitacicept as double-targeted therapy for myasthenia gravis coexisting with connective tissue disease: three case reports
Myasthenia gravis (MG) and connective tissue diseases (CTD) are both B-cell-mediated, antibody-associated autoimmune diseases that share similar mechanisms of immune dysfunction. The coexistence of MG and CTD is a rare phenomenon, and its management remains challenging. Here, we report three cases o...
Saved in:
| Main Authors: | Yingying Yang, Ying Zhu, Ruixia Zhu |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-05-01
|
| Series: | Frontiers in Immunology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fimmu.2025.1552521/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Efgartigimod Followed by Telitacicept in Adult Generalized Myasthenia Gravis: A Retrospective Case Series
by: Zhang Y, et al.
Published: (2025-04-01) -
Successful treatment of generalized myasthenia gravis with telitacicept: a Chinese case series and literature review
by: Xiaodong Song, et al.
Published: (2025-01-01) -
Telitacicept as an alternative to non-steroidal immunosuppressive therapies in the treatment of myasthenia gravis: a study on clinical efficacy and steroid-sparing effect
by: Zheyu Fang, et al.
Published: (2025-03-01) -
Case report: Efgartigimod is a novel therapeutic option for ocular myasthenia gravis: a report of 2 cases
by: Tianying Ma, et al.
Published: (2025-01-01) -
IMMUNOPATHOGENESIS OF MYASTHENIA GRAVIS (REVIEW)
by: E. D. Gasymly
Published: (2018-06-01)